Understanding vaccine safety information from the vaccine adverse event reporting system

被引:286
|
作者
Varricchio, F [1 ]
Iskander, J
Destefano, F
Ball, R
Pless, R
Braun, MM
Chen, RT
机构
[1] Food & Drug Adm, Ctr Biol Evaluat & Res, Off Biostat & Epidemiol, Div Epidemiol, Ottawa, ON, Canada
[2] CDCP, Natl Immunizat Program, Epidemiol & Surveillance Div, Immunizat Safety Branch, Ottawa, ON, Canada
[3] Hlth Canada, Ctr Infect Dis Prevent & Control, Immunizat & Resp Infect Div, Immunizat Safety Unit, Ottawa, ON K1A 0L2, Canada
关键词
adverse event; vaccine; vaccine adverse event reporting system (VAERS);
D O I
10.1097/00006454-200404000-00002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The Vaccine Adverse Event Reporting System (VAERS) is administered by the Food and Drug Administration and CDC and is a key component of postlicensure vaccine safety surveillance. Its primary function is to detect early warning signals and generate hypotheses about possible new vaccine adverse events or changes in frequency of known ones. VAERS is a passive surveillance system that relies on physicians and others to voluntarily submit reports of illness after vaccination. Manufacturers are required to report all adverse events of which they become aware. There are a number of well-described limitations of such reporting systems. These include, for example, variability in report quality, biased reporting, underreporting and the inability to determine whether a vaccine caused the adverse event in any individual report. Strengths of VAERS are that it is national in scope and timely. The information in VAERS reports is not necessarily complete nor is it verified systematically. Reports are classified as serious or nonserious based on regulatory criteria. Reports are coded by VAERS in a uniform way with a limited number of terms using a terminology called COSTART. Coding is useful for search purposes but is necessarily imprecise. VAERS is useful in detecting adverse events related to vaccines and most recently was used for enhanced reporting of adverse events in the national smallpox immunization campaign. VAERS data have always been publicly available. However, it is essential for users of VAERS data to be fully aware of the strengths and weaknesses of the system. VAERS data contain strong biases. Incidence rates and relative risks of specific adverse events cannot be calculated. Statistical significance tests and confidence intervals should be used with great caution and not routinely. Signals detected in VAERS should be subjected to further clinical and descriptive epidemiologic analysis. Confirmation in a controlled study is usually required. An understanding of the system's defined objectives and inherent drawbacks is vital to the effective use of VAERS data in vaccine safety investigations.
引用
收藏
页码:287 / 294
页数:8
相关论文
共 50 条
  • [1] Safety Data on Meningococcal Polysaccharide Vaccine from the Vaccine Adverse Event Reporting System
    Ball, R
    Braun, MM
    Mootrey, GT
    CLINICAL INFECTIOUS DISEASES, 2001, 32 (09) : 1273 - 1280
  • [2] Postmarketing Safety Surveillance of a Hexavalent Vaccine in the Vaccine Adverse Event Reporting System
    Moro, Pedro L.
    Zhang, Bicheng
    Marquez, Paige
    Reich, Jonathan
    JOURNAL OF PEDIATRICS, 2023, 262
  • [3] The vaccine adverse event reporting system and vaccine safety research in the genomics era
    Davis, Robert Lowell
    VACCINE, 2012, 30 (06) : 1162 - 1164
  • [4] The role of the vaccine adverse event reporting system (VAERS) in monitoring vaccine safety
    Iskander, JK
    Miller, ER
    Chen, RT
    PEDIATRIC ANNALS, 2004, 33 (09): : 599 - 606
  • [5] Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)
    Shimabukuro, Tom T.
    Nguyen, Michael
    Martin, David
    DeStefano, Frank
    VACCINE, 2015, 33 (36) : 4398 - 4405
  • [6] The Vaccine Adverse Event Reporting System
    Varricchio, F
    JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1998, 36 (07): : 765 - 768
  • [7] Vaccine-Adverse Event Reporting System: An essential tool for monitoring vaccine safety
    Hayney, Mary S.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2006, 46 (02) : 298 - 299
  • [8] Human Papillomavirus Vaccine Safety in Pediatric Patients: An Evaluation of the Vaccine Adverse Event Reporting System
    Borja-Hart, Nancy L.
    Benavides, Sandra
    Christensen, Crystal
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (02) : 356 - 359
  • [9] MONITORING VACCINE SAFETY BY STUDYING TEMPORAL VARIATION OF ADVERSE EVENTS USING VACCINE ADVERSE EVENT REPORTING SYSTEM
    Huang, Jing
    Cai, Yi
    Du, Jingcheng
    Li, Ruosha
    Ellenberg, Susan S.
    Hennessy, Sean
    Tao, Cui
    Chen, Yong
    ANNALS OF APPLIED STATISTICS, 2021, 15 (01): : 252 - 269
  • [10] Misinformation and the Vaccine Adverse Event Reporting System
    Jamieson, Kathleen Hall
    Johnson, Kevin B.
    Cappola, Anne R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (12): : 1005 - 1006